Evolution of the Average Target: Capricor Therapeutics, Inc.

Evolution of the Target Price: Capricor Therapeutics, Inc.

Changes in Analyst Recommendations: Capricor Therapeutics, Inc.

03cb080f4.CMytON9NndbBNFghpXHtmVLz3W_S8e5QBCsBo0_cW2U.Qq_kS715zuK0UG9i3xqI1iWdlyrgkrseMV1PlwG6IwJYifV_63vZgvhEAQ~50e46972584bdf0a22044a5f0b54445d
09-14 Capricor Therapeutics Shares Rise After Upgrade From B. Riley MT
09-14 B. Riley Upgrades Capricor Therapeutics to Buy From Neutral, Raises Price Target to $21 From $5 MT
09-01 Capricor Therapeutics Shares Rise After Piper Sandler Upgrade MT
09-01 Piper Sandler Upgrades Capricor Therapeutics to Overweight From Neutral, Adjusts PT to $25 From $2 MT
08-14 Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight From Neutral, Adjusts PT to $28 From $3.50 MT
07-31 B. Riley Adjusts Capricor Therapeutics Price Target to $5 From $10, Maintains Neutral Rating MT
07-30 Oppenheimer Downgrades Capricor Therapeutics to Perform From Outperform, Price Target is $54 MT
07-30 Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral From Overweight, Adjusts PT to $3.50 From $62 MT
07-30 HC Wainwright Downgrades Capricor Therapeutics to Neutral From Buy MT
07-28 Capricor Therapeutics Shares Fall After B. Riley, Roth Capital Downgrades MT
07-28 B. Riley Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $10 From $63 MT
07-28 Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38 MT
03-13 B. Riley Adjusts Price Target on Capricor Therapeutics to $63 From $50, Maintains Buy Rating MT
12-15 B. Riley Adjusts Price Target on Capricor Therapeutics to $50 From $21, Maintains Buy Rating MT
12-08 Oppenheimer Adjusts Capricor Therapeutics PT to $54 From $22, Maintains Outperform Rating MT
25/09/25 Capricor Therapeutics Shares Rise After FDA Aligns on Endpoints for DMD Therapy Trial MT
25/09/25 Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy CI
26/06/25 B. Riley Initiates Coverage on Capricor Therapeutics With Buy Rating, $21 Price Target MT
23/06/25 Oppenheimer Lowers Capricor Therapeutics Price Target to $22 From $43, Maintains Outperform Rating MT
20/05/25 Roth Capital Initiates Coverage on Capricor Therapeutics With Buy Rating MT
18/11/24 JonesTrading Initiates Capricor Therapeutics at Buy Rating With $40 Price Target MT
21/10/24 Piper Sandler Initiates Capricor Therapeutics at Overweight With $35 Price Target MT
25/09/24 Oppenheimer Adjusts Capricor Therapeutics Price Target to $43 From $15, Maintains Outperform Rating MT
24/09/24 Cantor Fitzgerald Adjusts Capricor Therapeutics Price Target to $25 From $8, Maintains Overweight Rating; Shares Rise MT
18/09/24 Oppenheimer Adjusts Capricor Therapeutics Price Target to $15 From $14, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+215.42%
+19.4%
+18.95%
+66.4%
+18.1%
+22.48%
+14.13%
+15.96%
+67.21%
+34.01%
Average +49.21%
Weighted average by Cap. +26.97%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
8.560USD
Average target price
27.00USD
Spread / Average Target
+215.42%
High Price Target
54.00USD
Spread / Highest target
+530.84%
Low Price Target
7.000USD
Spread / Lowest Target
-18.22%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. CAPR Stock
  4. Consensus Capricor Therapeutics, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!